Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

AstraZeneca plc. (2/2/18). "Press Release: Full-Year 2017 Results".

Organisation Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product Brilinta®
  Product 2 Farxiga®
Person Person Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“AstraZeneca’s revenues improved over the course of the year, a sign of how our company is steadily turning a corner. Strong commercial execution helped us bring our science to more patients, making the most of our exciting pipeline. We made encouraging progress across the main therapy areas and delivered strong growth in China.

Alongside our CVMD medicines Brilinta and Farxiga reaching blockbuster status, we launched our first Respiratory biologic medicine, Fasenra and new cancer medicines, Imfinzi and Calquence. As well as bringing five new medicines to patients last year, we continued to find more potential uses for existing treatments, including Lynparza and Tagrisso.

We remain committed to our progressive dividend policy. Our strategy is working, propelled by a strong pipeline, good sales performance and continued cost discipline.”


Full-Year 2017 Results announcement (PDF 1.6mb) [ ]

Full-Year 2017 Results investor presentation (PDF 4.4mb) [ ]

Full-Year 2017 Clinical trials appendix (PDF 1.7mb) [ ]

Record changed: 2018-02-08


Picture [LSUS] – The Business Web Portal 600x60px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top